ICARE Newsletter Summer 2018

Updates to NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian Guidelines

(Version 1.2019, posted July 11, 2018)

  • Regardless of family history, some individuals with a hereditary breast- and ovarian-related cancer may benefit from genetic testing to determine eligibility for targeted treatment
  • The multi-gene testing section table was updated with:
    • A potential association of ATM with ovarian cancer risk
    • Potential increased risk of BARD1 with breast cancer
    • Risk of breast cancer in BRIP1 was changed from no increased risk to unknown/insufficient evidence

For the complete updated versions of the NCCN Guidelines, please visit NCCN.org

admin

Permanent link to this article: https://inheritedcancer.net/1nls2018/